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Abstract
Background: Despite significant achievements in the treatment of cervical cancer, it is still a
deadly disease; hence newer therapeutical modalities are needed. Preliminary investigations suggest
that platelet-derived growth factor (PDGF) might have a role in the development of cervical cancer,
therefore it is important to determine whether this growth factor pathway is functional and its
targeting with imatinib mesylate leads to growth inhibition of cervical cancer cells.
Results: PDGF receptors (PDGFR) and their ligands are frequently expressed in cervical cancer
and the majority exhibited a combination of family members co-expression. A number of intronic
and exonic variations but no known mutations in the coding sequence of the PDGFRα gene were
found in cancer cell lines and primary tumors. Growth assays demonstrated that PDGFBB induces
growth stimulation that can be blocked by imatinib and that this tyrosine kinase inhibitor on its own
inhibits cell growth. These effects were associated with the phosphorylation status of the receptor.
Conclusion: The PDGFR system may have a role in the pathogenesis of cervical cancer as their
members are frequently expressed in this tumor and cervical cancer lines are growth inhibited by
the PDGFR antagonist imatinib.
Background
Cervical cancer remains as one of the biggest killers of
women worldwide [1]. The oncogenic role of human pap-
illomavirus for the development of this cancer has been
vastly demonstrated [2], however, an unknown number
of genetic [3] and epigenetic [4] defects are also needed
for tumor formation, such as alterations in the epidermal
growth factor receptor (EGFR) and other membrane
receptors [5]. Abnormalities in platelet derived growth
factor (PDGF) family members have been underscored as
important players for neoplasms such as meningiomas,
gliomas, melanomas, neuroendocrine tumors, sarcomas
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and ovarian, pancreas, gastric, lung, breast and prostate
carcinomas [6-8]. PDGF is a potent mitogen and chemo-
tactic factor for mesenchymally derived cells, and was one
of the first polypeptidic growth factors identified that sig-
nals through a cell surface tyrosine kinase receptor
(PDGFR), to stimulate various cellular functions includ-
ing growth, proliferation, and differentiation. Since then,
several related genes have been identified constituting a
family of ligands (PDGFA B, C and D) and their cognate
receptors (PDGFR alpha and beta) [9-11]. PDGF isoforms
are dimeric molecules that bind two receptors simultane-
ously which dimerize upon binding. These receptors may
generate homo- or heterodimers resulting in the next
combinations PDGFRαα, αβ or ββ. The PDGFRα is able
to bind to PDGF chains A, B and C, while PDGFRβ binds
only PDGF chains B and D [12]. Interestingly, the het-
erodimeric receptor complex αβ have different properties
compared to the homodimers [13].
The recent availability of potent and specific tyrosin
kinases inhibitors such as imatinib mesylate, which was
developed as an ATP competitive inhibitor of ABL tyro-
sine [14] that, at concentrations required for inhibition of
Bcr-Abl, also inhibits PDGFR and c-Kit [15], has revived
the interest on the PDGFR as potential therapeutic target
for several neoplasms, including solid tumors [16,17].
Regarding cervical cancer, the role of the PDGFR system
remains to be explored. So far there are some indications
that PDGFR could participate in the HPV-driven carcino-
genic process. It has been shown that transformation by
the bovine papillomavirus type 1 (BPV-1) E5 protein
binds to and activates PDGFRβ inducing its dimerization
and sustained activation similarly to PDGF [18,19]. Fur-
ther, it was proven that the E5-induced tyrosine phospho-
rylation or mitogenic activity of the receptor is ligand
PDGFR independent. Thus, it seems that PDGFRβ is the
main cellular target of the BPV-E5 oncoprotein [20,21].
Little is known regarding the PDGF and PDGFR expres-
sion in cervical cancer. There is only one small study
where the expression of the PDGFR protein was investi-
gated in 11 patients with mild, moderate or severe dyspla-
sia as well as four invasive cervical cancers. Expression of
PDGFRβ was observed at high levels in low-grade cervical
lesions, while expression was depressed in high-grade
lesions, suggesting a role for PDGFR during early stages of
cervical carcinogenesis [22].
On the other hand, PDGFRβ participates in the regulation
of interstitial fluid pressure (IFP), by modulating the ten-
sion between cells and extracellular matrix structures [23].
Subsequently it was demonstrated that IFP is elevated in
most malignant tumors, mainly as a result of the abnor-
mal tumor vasculature that develops from unregulated
angiogenesis, resulting in a diminished hydrostatic gradi-
ent from capillary to interstitium and thereby impairing
the exchange of solutes over the capillary membrane, cre-
ating a physiological barrier to tumor uptake of drugs
from circulation [24,25]. Increased interstitial fluid pres-
sure has also been demonstrated in cervical cancer
patients [26]. Interestingly, a prospective study in 102 cer-
vical cancer patients, demonstrated a strong independent
prognostic value of pre-treatment IFP measurements in
tumors. Patients with high IFP are significantly more
likely than those with low IFP to recur after radiotherapy
and die of progressive disease [27].
It has been demonstrated that not only overexpression of
PDGFR participates in carcinogenesis; also genetic
changes have a role in this process. So far, Heinrich dem-
onstrates that activating gene mutations of PDGFRα in
GISTs have biological consequences, highlighting a cru-
cial role for PDGFRα in the pathogenesis of a solid tumor
[28]; in fact some of this mutations induce imatinib resist-
ance [29].
All together these data clearly suggest that blocking the
PDGFR system would be of terapeutical value in cervical
cancer, hence in this work we analyzed the expression of
PDGF family members as well as the mutational status of
the PDGFRα gene in a series of cervical cancer cell lines
and primary tumors of cervical cancer patients. In addi-
tion, the growth inhibitory effect of imatinib was also
investigated in a cervical cancer cell line.
Results
Expression of PDGF family members in cervical cancer cell 
lines
Expression of PDGF ligands and receptors was investi-
gated in eight cervical cancer cell lines. The results, pre-
sented in Table 1 demonstrate that all cell lines tested,
expressed PDGFRα but none expressed PDGFRβ. In
regard to the ligands, the PDGFB was present in five
(62.5%) out of eight cell lines whereas 50% (4 out of 8)
of the cell lines expressed PDGFA. Interestingly, all cell
lines co-expressed the PDGFRα with at least one of the lig-
Table 1: Expression of PDGF family members in cervical cancer 
cell lines.
Cell line PDGFRα PDGFA PDGFRβ PDGFB
C33A + - - +
INBI + - - +
ViPa + - - +
ViBo + - - +
HeLa + + - -
SiHa + + - -
CaLo + + - +
CasKi + + - -
Cell lines were analyzed by immunocytochemistry. CaLo cells co-
expressed the receptor alpha and both ligands. Positivity was 
considered when 5% or more of the cell population stained.Cancer Cell International 2006, 6:22 http://www.cancerci.com/content/6/1/22
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ands. There was only one cell line (CaLo) which co-
expressed both ligands along with the receptor. Hence this
cell line was chosen for further testing.
Expression of PDGF family members in primary tumors
The immunohistochemical expression of PDFG and
PDGFR family members was evaluated in the primary
tumors of 36 patients. Biopsies were taken before the
patients received any anticancer therapy; mean age for the
patients was 40.8 years; 6 patients were staged as IB2-IIA,
14 as IIB and 16 as IIIB; 32 and 4 were histologically clas-
sified as squamous and adeno/adenosquamous respec-
tively. The immunohistochemistry results are shown in
Figure 1. Overall, PDGFRα was expressed in the malignant
cell component of the sample in 15 (41.6%) of cases, 3 of
them (8.3%) showed positive reaction in tumor cells as
well as in stroma; and in 2 cases (5.5%) only in the stroma
Regarding the PDGFRβ, 19 samples (52.7%) expressed
the receptor in the tumor component, 13 out of the 19
samples showed signal in tumor and stroma; 4 cases
(11.1%) were positive only in the stroma. PDGF ligands
were evaluated only in 25 samples because of sample lim-
itations. PDGFA was expressed in 15 cases (60%) in the
tumor cell component; 17 samples (68%) stained in the
stroma, 14 of them were positive in both components,
while 3 (12%) only in the stroma. None of the samples
expressed the PDGFB. Representative cases are shown in
Figure 2.
Mutational analysis of the PDGFRα gene
To further characterize the potential participation of
PDGFR in cervical cancer development and to determine
the presence of gene-activating mutations or mutations
associated to imatinib resistance, we performed a muta-
tional analysis of the PDGFRα exons 12 and 18 in the
DNA extracted from the 8 cell lines and the frozen cervical
tumors. Table 2 shows that cell lines ViPa, HeLa, CaLo
and INBL were wild type for the exon 12 and presented a
silent mutation in codon 824 C>T leading to a Val>Val
change (SNP rs10015469, previously reported) in exon
18. On the other hand, C33, CasKi and SiHa cells were
wild type for exon 18 but showed a G>A in codon 571
leading to a Glu>Lys substitution (unreported changes).
Interestingly ViBo cell line had three silent mutations at
exon 12 and two intronic variations, whereas in exon 18
no exonic variations but two intronic variations were
found. Regarding the analysis of the 17 tumor samples, all
were wild type for exon 12. At exon 18, seven patients
were wild type and ten had the same silent mutation
found in cell lines at codon 824 (Table 3). Regarding nor-
mal tissues, we performed the sequence analysis in three
cervical tissues and in the lymphocytes from 8 healthy
donors, the three cervical samples had the codon 824
silent mutation in exon 18 and, two of them presented an
intronic polymorphism in exon 12 (Table 3). All the lym-
phocyte donors were wild type for exon 12 and three of
them had the silent mutation at codon 824 (data not
shown).
Expression of PDGF family members in primary tumors Figure 1
Expression of PDGF family members in primary tumors. In 
this figure we show the co-expression of receptors and lig-
and in each sample. Gray boxes indicate positivity, white neg-
ativity and line-drawing not done. Summary of the results is: 
PDGFRα: 15 cases (41.6%) were positive in tumor cells, of 
these, 3 cases show expression in tumor and stroma cells. 
Two cases were positive only in stroma (5.5%). PDGFRβ: 
19 cases (52.7%) were positive in tumor cells, of these 13 
samples show expression in both tumor and stoma cells. 
Four tumors were positive only in stroma cells (11.1%). 
PDGFA: 15 cases (60%) were positive at the tumor compo-
nent, 14 of them in both tumor and stroma; 3 cases (12%) 
positive only in stroma. PDGFB: All negative
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Cell proliferation
In order to investigate whether the PDGF system has a role
in regulating cell growth, the cell line CaLo which co-
express three family members, was grown for two days in
the absence of serum and then re-plated for treatment
with imatinib, recombinant PDGFBB or both for five
days. The results show that the ligand BB led to a 37%
growth stimulation as compared to the untreated control
(p < 0.001). On the contrary imatinib induced a statisti-
caly significant growth inhibition as compared to
untreated control (p < 0.001); and when cells were co-
treated with the ligand and imatinib, the growth-inducing
activity of the PDGFB was partly blocked by imatinib (p <
0.001), (Figure 3a).
PDGFRα phosphorylation
The growth assays clearly demonstrated that in this
model, cells are responsive to the growth stimulatory
effect of the PDGFBB which can be partly blocked by the
PDGFR kinase inhibitor imatinib. To assess whether this
effect was associated with receptor activation, serum
deprived CaLo cells were transiently stimulated with the
PDGFBB for 15 min in the presence or absence of imat-
inib, and then analyzed by western blot with an antibody
against the phosphorylated PDGFRα. Figure 3b shows
that in untreated control cells, there was a basal level of
receptor phosphorylation which increased after stimula-
tion with the growth factor, but was inhibited to a similar
degree of untreated cells by imatinib treatment.
Discussion
Treatment results of locally advanced cervical cancer are
suboptimal despite the recent success of first line therapy
with concurrent chemoradiation [31,32]; or with and cis-
platin plus topotecan for recurrent and metastatic [33].
Nevertheless, it is necessary to evaluate newer forms of
therapy. Preclinical and clinical development of newer
agents targeting molecular defects present in tumors [34]
Representative samples of primary tumors expressing: a) PDGFRα, b) PDGFA and c) PDGFRβ. (100X). d) shows the staining  for PDGFRα in the cell line CaLo (400X) Figure 2
Representative samples of primary tumors expressing: a) PDGFRα, b) PDGFA and c) PDGFRβ. (100X). d) shows the staining 
for PDGFRα in the cell line CaLo (400X).
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c dCancer Cell International 2006, 6:22 http://www.cancerci.com/content/6/1/22
Page 5 of 11
(page number not for citation purposes)
open the way for the identification of molecular targets in
cervical cancer.
The availability of the tyrosin kinase inhibitor imatinib
which not only targets bcr/abl but also c-kit and PDGFR
Table 3: Sequence analysis of PDGFRA exons 12 and 18 from primary cervical cancer tumors and normal cervix samples.
SAMPLE EXON 12 EXON 18
localization change position amino acid localization change position amino acid
CU-194 WT WT
CU-493 WT Exon C >T GTC>GTT ht Codon824 Val > Val
CU-693 WT WT
CU-794 WT Exon C >T GTC>GTT hm Codon 824 Val > Val
CU-1094 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-1194 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-1494 WT WT
CU-1593 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-2294 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-3194 WT Exon C >T GTC>GTT hm Codon 824 Val > Val
CU-3293 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-3994 WT Exon C >T GTC>GTT hm Codon 824 Val > Val
CU-4594 WT WT
CU-4793 WT WT
CU-4994 WT WT
CU-5393 WT WT
CU-5593 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CN-893 Intron C > A IVS12 +22 ------ Exon C >T GTC>GTT ht Codon 824 Val > Val
CN-993 Intron C > A IVS12 +22 ----- Exon C >T GTC>GTT ht Codon 824 Val > Val
CN-994 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
HD WT WT
WT: wild type; IVS: intronic variation sequence; ht: heterozygous; hm: homozygous. CU = cervical cancer, CN = non-neoplastic cervix, HD = 
healthy donor lymphocytes. The polymorphisms were presented as ht = heterozygous or hm = homozygous. [RefSeq accession D50017]. All 
patients were wild type in exon 12, and 10 out of 17 had the silent mutation C >T in codon 824 GTC>GTT, Val>Val [rs10015469]. 2 samples of 
non-neoplastic cervical tissue presented the intronic variation C>A IVS12+22 [rs2307051] and all 3 presented the silent mutation in codon 824 
[rs10015469]. In this table we show the results of only one lymphocytes donor, but all 8 donors were wild type for exon 12, and 3 out of 8 
presented the polymorphism at codon 824.
Table 2: Sequence analysis of PDGFRα exons 12 and 18 from eight primary cervical cancer cell lines.
CELL LINE EXON 12 EXON 18
localization change position amino acid localization change position amino acid
ViBo Exon G>A CCA >CCG Codon 567 Pro > Pro Intron C >G IVS18 +21 ---
Exon G>A CCA >CCG Codon 577 Pro > Pro Intron A >G IVS18 +25 ---
Exon A>G TCA >TCG Codon 584 Ser > Ser -----
Intron A> G IVS12 +17 ---- -----
Intron T> C IVS12 +35 ---- -----
ViPa WT Exon C >T GTC>GTT Codon 824 Val > Val
HeLa WT Exon C >T GTC>GTT Codon 824 Val > Val
CaLo WT Exon C >T GTC>GTT Codon 824 Val > Val
INBL WT Exon C >T GTC>GTT Codon 824 Val > Val
C33 Exon G >A GAA>AAA Codon 571 Glu > Lys WT
Caski Exon G >A GAA>AAA Codon 571 Glu > Lys WT
SiHa Exon G >A GAA>AAA Codon 571 Glu > Lys WT
WT: wild type; IVS: intronic variation sequence. We found 7 intronic and 5 exonic variations sequences [RefSeq accession D50017]. None of the 
intronic variations have been reported: for exon 12 we found, A >G IVS12+17 and T >C IVS12+35, and for exon 18, C >G IVS18+21 and A >G 
IVS18+25. The exonic changes were: G >A in codon 567 CCA >CCG, Pro>Pro [rs1873778] synonimous; G>A codon 577 CCA >CCG, Pro >Pro 
(unknown) synonimous; C >T in codon 824 GTC >GTT, Val >Val [rs10015469] synonimous; G >A codon 571 CCA >CCG, Glu > Lys (unknown) 
not deleterious; and A >G in codon 584 CCA >CCG, Ser > Ser (unknown) synonimous.Cancer Cell International 2006, 6:22 http://www.cancerci.com/content/6/1/22
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a) Effect of imatinib in cervical cell line growth Figure 3
a) Effect of imatinib in cervical cell line growth. CaLo cells were grown for two days in the absence of serum and then re-plated 
for treatment with imatinib, PDGFββ or both for five days. PDGFBB stimulated cell gowth as compared to the untreated con-
trol. On the contrary imatinib induced growth inhibition and when cells were co-treated with the ligand and imatinib, the 
growth-inducing activity of the PDGFBB was partly blocked by imatinib (comparison are marked with * or ^, all these differ-
ences were statistically significant p < 0.001). Their corresponding pictures of the plates stained with crystal violet is shown 
below. b) Inhibition of phosphorylation of PDGFRα by imatinib. CaLo cells were stimulated with PDGFBB at 10 ng/mL, for 10 
min; treated with imatinib at 10 μM for 2 hours; treated with imatinib for two hours and then with PDGFBB for 15 min; or no 
treatment as control. Equal loading confirmed with actin. Receptor phosphorylation is increased in the PDGFBB lane and inhib-
ited by imatinib treatment.
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has led to investigate the participation of these two recep-
tors in several solid malignancies, particularly in small cell
lung cancer and prostate carcinoma which over-express
the c-kit receptor. However, early results using imatinib as
a single agent have not been encouraging [35-37] which
suggests that the sole presence of the putative target may
not be sufficient to achieve tumor responses, besides, it is
necessary to demonstrate that the pathway is functional
and of relevance for one or more characteristics of the
malignant phenotype in the tumor to be targeted.
So far, the role of the PDGFR pathway for the develop-
ment of cervical cancer has been only studied in in vitro
models, derived from the observation of the interaction
between the E5 papilloma virus protein with the PDGFR
[19,20]. There is a single study showing that the four pri-
mary cervical cancers analyzed by immunohistochemistry
expressed the PDGFRβ [22]. In several tumors, where the
participation of PDGF family has been demonstrated, a
simultaneous expression of the receptors and the ligands
seems to be important, suggesting an autocrine stimula-
tion mechanism [38]. In the present study we evaluated a
larger sample of primary tumors for the expression of the
ligands and receptors of PDGF at both the malignant and
stroma components of the biopsy. The expression of these
growth factor family members in stroma is important as
they are regulators of mesenchymal cell proliferation and
migration during development, and therefore could play
important roles in stromal fibroblast recruitment and
tumor progression [39,40].
Our results indicate that around half of the tumors express
the PDGFRα, PDGFRβ and PDGFA, in both tumor and
stroma as shown in Figure 1. We found no expression of
the B ligand in tumor samples, which was surprising as 5
out of 8 cervical cancer cell lines expressed this ligand. In
addition, both ligands have been found expressed in a
number of other tumor types [9]. Whether this feature is
unique to primary cervical cancer tumors merits further
study.
Interestingly 78% of the primary tumors express either the
alpha or beta receptor. This elevated frequency of expres-
sion and co-expression highly suggest autocrine and para-
crine functioning in cervical cancer tumors. This high
frequency of expression and co-expression also occurred
in the cervical cancer cell lines studied. It has been shown
that the sole expression of PDGF receptors correlates with
known adverse prognostic factors such as axillary lymph
node metastases in breast cancer [28]. However, in this
study we found no correlation between any combination
of PDGF members expression with neither clinical charac-
teristics of patients nor survival (data not shown). This
observation does not exclude the possible prognostic sig-
nificance of these receptors in cervical cancer. We also
studied the mutational status of the PDGFRα, based on
the identification of activating gene mutations within a
subset of GISTs that lacked KIT gene mutation, and where
constitutive phosphorylation of PDGFRα was observed,
and the corresponding PDGFRα isoforms demonstrated
ligand-independent kinase activity [29]. These observa-
tions have profound implications for the treatment of
solid tumors with imatinib, as some of these mutations
confer either sensitivity or resistance to this tyrosine
kinase inhibitor [41]. This can be explained on the lack of
differences in the activation of downstream signaling
intermediates between KIT-mutant and PDGFRα-mutant
tumors, suggesting that mutant PDGFRα provides onco-
genic signals that parallel those of mutant KIT [29].
Our sequence results indicate that the cervical cancer cell
lines and primary tumors analyzed showed a number of
intronic and exonic variations, most of them previously
unreported, (Tables 2 and 3). The mutation G>A in codon
571 leading to a Glu>Lys substitution found in three of
the cell lines has not been reported; however, the dele-
tion/substitution SPDGHE566-571R (already reported)
involves codon 571 which corresponds to the juxtamem-
brane domain of the protein. The significance of this
change in regard to imatinib sensitivity is unknown [42]
but this deletion increases PDGFRα activation in the pres-
ence of PDGFA [29] suggesting that the mutation that we
found, could affect the PDGFRα functioning. In an
attempt to study the possible effect of this mutation on
the protein, we used the simulation program PolyPhen
[43] to predict whether this mutation, found in the cell
lines, is likely to have biological meaning. The results
indicate that the G>A at codon 571 of exon 12 is "bening".
It is clear however, that this is only a theoretical approxi-
mation hence; the meaning of changes found must be
investigated in experimental systems [44]. Besides, most
of the intronic changes that we found are located in the
proximity of the exon boundaries, and their possible
meaning has to be studied. Regarding the samples from
patients, we found the silent mutation at codon 824
already reported, in 10 out of 17 patients (59%). In the
normal cervical samples, we found that 6 out of 11 pre-
sented the polymorphism at codon 824 (55%), indicating
that this polymorphism is very common in our popula-
tion. In exon 12, two samples presented the intronic
change C>A IVS12+22 already reported [rs2307051] with
no known consequence.
As stated above, the sole expression of the PDGFR or lig-
and is not an indication that the pathway is functional
and that regulates the growth of the expressing tumor.
Hence, we wanted to evaluate whether CaLo cell line
which express the receptor alpha and both ligands is
responsive to the growth factor and its inhibitor. Our
results clearly demonstrate that while CaLo cells exhibitCancer Cell International 2006, 6:22 http://www.cancerci.com/content/6/1/22
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growth stimulation by PDGFBB, imatinib has on their
own a small but significant growth inhibitory effect in
serum-deprived cells, and that imatinib also partly blocks
the PDGFB-induced growth stimulation. These effects on
growth are likely due to activation of the PDGFR pathway
as the results of western blots employing a primary anti-
body specific for the activated form of the receptor alpha
indicate phosphorylation after the stimulation with
PDGFBB, and that is back to unstimulated levels upon
exposure to imatinib. It is noteworthy however, that in
untreated cells despite being inhibited in their growth by
imatinib, the basal level of phosphorylation of the recep-
tor was unchanged after imatinib treatment, which may
suggest that under the experimental conditions tested, the
method has not enough sensitivity to detect a certain
degree of phosphorylation inhibition. Even that we did
not evaluate the activation of known downstream phos-
phorylation targets of the PDGFR pathway, the results
demonstrate that as observed in other tumors such as
osteosarcoma [45] and ovarian carcinoma [38], the block-
ing of this pathway could have therapeutical implications.
Nevertheless, further functional characterization of the
pathways either Src-PI3K-ERK, JNK1-p21 or other [46],
known to be activated by PDGFR stimulation in other sys-
tems, is needed in order to optimize the potential use of
PDGFR inhibitors in this malignancy. Likewise, is desira-
ble to increase the number of primary tumors tested for
activating mutations of the PDGFR to rule out the exist-
ence of activating mutations at this receptor that could be
specifically blocked by PDGFR inhibitors. In addition, it
remains to be explored whether the in in vivo blocking the
receptor affects the interstitial pressure and would facili-
tate drug penetration into tumors.
Conclusion
This study shows that members of the PDGF system are
expressed in cervical cancer cell lines and primary cervical
cancer tumors. In addition it is shown that the PDGFRα
gene has several intronic and exonic changes but none of
them biologically relevant. More interestingly, the results
demonstrate that in a cervical cancer cell line, the system
is functional as recombinant PDGFBB induces cell growth
and receptor phosphorylation which can be blocked by
imatinib. Despite the absence of activating mutations of
PDGFRα, the co-expression of PDGF receptors and
PDGFA in both the malignant cell component and stroma
of the tumors, suggests the existence of an autocrine/para-
crine growth stimulation loop which can be blocked by
imatinib.
Methods
Cell lines and reagents
DMEM culture media and Fetal Calf Serum were pur-
chased from Gibco BRL Life Technologies (Grand Island,
New York). HeLa, CasKi, SiHa and C33A were obtained
from the ATCC, ViBo, INBL, ViPa and CaLo carcinoma cell
lines were kindly provided by Dr. Monroy (FES Zaragoza,
UNAM, Mexico City). Cells were routinely grown in
DMEM supplemented with 10% FCS at 37°C and 5%
CO2. For immunocytochemistry analyses, cells were
grown on two-chamber polysterene vessel Falcon® (Bec-
ton Dickinson, NJ.) and subsequently formalin-fixed for
24 hrs at room temperature, then rehydrated in graded
ethanol. Afterwards immunochemistry was performed as
below described.
Cervical cancer samples
Thirty-six paraffin-embedded tumor tissues from patients
FIGO staged as IB2 to IIIB, treated with standard radiation
concurrent with weekly cisplatin. Diagnosis was made on
the basis of routine hematoxilin-eosin examination under
light microscopy according to the World Health Organiza-
tion criteria. Tumor specimens at diagnosis were taken
before any treatment was instituted. For the mutational
analysis of the PDGFRα 17 frozen samples of cervical can-
cer from an unrelated study were used. Biopsies from nor-
mal cervix and lymphocytes from 8 healthy donors were
taken from a tissue bank.
Immunohistochemistry
Immunohistochemistry for the PDGFRs and their ligands
was performed using standard procedures. Briefly, sec-
tions were deparaffinized in xylene and rehydrated
through graded ethanols to distilled water. The sections
were immersed in Dako Epitope Retrieval Solution (10
mM citrate buffer, pH6) that had been preheated to 95°C
in a water bath and then heat-treated at 95°C for 40 min.
After a 20-minute cooldown period at room temperature,
the sections were washed with PBS buffer, a procedure
that followed every subsequent incubation. Endogenous
peroxidase was blocked with Dako Blocking Buffer (0.3%
hydrogen peroxide containing 15 mM sodium azide) for
5 min at room temperature. The sections were incubated
for 30 min at room temperature with the following anti-
bodies used at 1:75 dilution: PDGFA (monoclonal anti-
body sc-9974), PDGFB (polyclonal antibody sc-7878),
PDGFRα (polyclonal antibody sc-338) and for PDGFRβ
(monoclonal antibody sc-6252) all four from Santa Cruz
Biotechnology. Bound primary antibody was labeled by
incubating the slides with the Dako Visualization reagent
(Dako EnVision + System, peroxidase (DAB, K-4007 and
K4011). The sections were counterstained with hematox-
ylin and eosin. Tissues used as positive controls were pla-
centa for both ligands, and normal skin for the receptors.
In the negative controls, the primary antibody was
ommited. Positivity was considered when 5% or more of
the malignant cell population or the stroma stained. The
analysis was performed by two pathologists.Cancer Cell International 2006, 6:22 http://www.cancerci.com/content/6/1/22
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PCR-sequencing
For PDGFRα mutational analysis, genomic DNA derived
from frozen samples and lymphocytes from 8 donors, was
extracted following conventional techniques, with protei-
nase K digestion followed by phenol:chloroform extrac-
tion.  PDGFRα  DNA was amplified by PCR using the
following primers: exon 12 forward: 5'-aagctctggtgcact-
gggactt-3' and reverse: 5'-attgtaaagttgtgtgcaaggga-3', prod-
uct size 251 bp; exon 18 forward: 5'-
tacagatggcttgatcctgagt-3' and reverse: 5'-agtgtgggaggat-
gagcctg-3', product size 212 bp. PCR was performed in 25-
μL reactions containing 200 ng DNA, 10 mmol/L Tris-HCl
(pH 8.3), 40 mmol/L KCl, 2 mmol/L MgCl2, 200 μmol/L
of each dNTP, 1 μmol/L of each primer, and 0.25 U Taq
polymerase (Applied Biosystems). PCR reaction was car-
ried out on an 2400 Thermalcycler (Applied Biosystems).
Initial denaturation at 94°C for 5 minutes was followed
by 40 cycles of amplification and a final extension step (5
minutes at 72°C). The cycles included denaturation at
94°C for 30 seconds, annealing at 60°C for 30 seconds,
and extension at 72°C for 30 seconds. PCR amplicons
were purified using isopropanol precipitation and then
sequenced in both forward and reverse directions from at
least two independent amplification products. Purified
DNA was diluted and cycle-sequenced using the ABI
BigDye Terminator kit v3.1 (ABI, Foster City, CA) accord-
ing to manufacturer's instructions. Sequencing reactions
were electrophoresed on an ABI3100 genetic analyzer.
Electropherograms were analyzed in both sense and anti-
sense direction for the presence of mutations.
Cell proliferation
CaLo cells were harvested in 75-cm2 flasks, washed twice
with PBS, and transferred in serum-free medium into 12-
well plates at a seeding density of 1 × 103 cells/well. Each
treatment group was plated in triplicate which consisted
in: no treatment, recombinant human PDGF-BB at 10 ng/
mL, Imatinib at 10 μM (freshly prepared in ddH2O) from
a commercial presentation) and both, the ligand and
imatinib. Fresh medium containing these treatments was
replaced at day 3. Cells were harvested after five days of
treatment and analyzed by the crystal violet method as
reported [30]. Briefly, cells were incubated in 0.1% crystal
violet for 30 min at room temperature, excess dye was
removed by three brief rinses with ddH2O, the plates were
air dried, and the dye was extracted with 10% acetic acid,
which was then read in a plate reader (Wallac 1420; Per-
kin Elmer, Boston, MA, USA) at 570 nm. This method has
shown to give an absorbance that correlates linearly with
the number of cells over the range 1000 to 50,000 cells/
well [30]. Assays were performed in triplicate and data are
presented as a mean and SD. Statistical analysis of cell
proliferation results was done using the ANOVA test.
Western Blot analysis
CaLo cells were cultured with complete medium in 75-
cm2  flasks and when reached a 50–75% confluence,
washed twice with PBS and replenished with serum-free
medium for two days. Cells were then stimulated with
PDGF BB at 10 ng/mL, for 10 min; treated with Imatinib
at 10 μM for 2 hours; treated with imatinib for two hours
and then with PDGF BB for 15 min; or no treatment as
control. Cells were washed with ice-cold PBS solution and
lysed in 0.2 mL of lysis buffer (Cell Signaling Technolo-
gies, Beverly, MA) at 4°C for 30 min. Lysates were cleared
by a 10-min centrifugation at 10,000 × g, and protein
determination was carried out according to the method of
Bicinchoninic acid. Samples were subjected to 8% PAGE
analysis after they were boiled for 5 min in sample buffer
containing SDS. The separated proteins were transferred
to an Hybond-P membrane (Amersham, Biosciences UK)
and then blocked for 1 h in TBS (1× Tris-buffered saline)
containing 5% nonfat milk. The membrane was then
incubated with primary antibody in TBS overnight at 4°C.
Primary antibody for p-PDGFRα, (Tyr 754 sc-12911-R,
Santa Cruz Biotechnology, CA). Equal loading of protein
samples (20 μg) was confirmed by incubating membranes
with a primary antibody specific for actin (Santa Cruz Bio-
technology). Membranes were washed and then incu-
bated for 1 h at room temperature with secondary
antibody. Bound antibody was detected using enhanced
chemiluminescence reagent (ECL; Biosciences UK).
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